We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA cleared GlaxoSmithKline's (GSK) nasal spray Veramyst April 27 for the "treatment of symptoms of seasonal and perennial rhinitis in adults and children 2 years of age and older." Read More
Sales of Roche's antiviral Tamiflu are on target to top the $1 billion mark this year, but the company has announced demand from government stockpiling initiatives is winding down. Read More
Boston Scientific's first-quarter results are "good enough," with implantable cardioverter-defibrillator (ICD) sales improving, but the company's drug-eluting stent sales "once again showedsignificant weakness," an RBC Capital Markets analyst report said. Read More
Sales of Roche's antiviral Tamiflu are on target to possibly top the $1 billion mark this year, but the company has announced demand from government stockpiling initiatives is winding down. Read More
Bristol-Myers Squibb (BMS) announced a deal under which it may receive up to $1 billion for working with Pfizer to develop and commercialize the anticoagulant apixaban. Read More
Millennium Research Group's (MRG) Marketrack service demonstrates increases in usage in the peripheral vascular market (PV) in Q1 2007 compared to Q1 2006, suggesting a promising year for the industry. Read More
Gebauer Company, a 107-year-old medical device manufacturer and marketer, announced a nationwide, voluntary, company-initiated recall of certain lots of topical skin refrigerant products, including Gebauer's Spray and Stretch, Gebauer's Pain Ease Mist and Medium Stream, Gebauer's Instant Ice Mist and Medium Stream. Read More
Novartis AG said Wednesday it will pay Cytos Biotechnology AG up to 600 million Swiss francs (US$500 million; 366 million) for the exclusive right to develop, produce and market an experimental drug it hopes will help cure smokers of their habit. Read More
U.S. drugmakers Bristol-Myers Squibb (BMS) and Pfizer have announced a worldwide collaboration to develop and commercialize apixaban, an anticoagulant discovered by BMS. Read More
Kirin Brewery has been granted Japanese manufacturing and marketing approval for its darbepoetin alfa product, a long-acting erythropoiesis-stimulating agent (ESA), under the name NESP injection. Read More